Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

cIMPACT-NOW Update 12: Refining pathology-based risk stratification and grading for IDH-mutant gliomas.

Neuro-oncology - 1 Sept 2026

Brat Daniel J, Aldape Kenneth, French Pim J, Louis David N, Nasrallah MacLean P, Reifenberger Guido, Reuss David E, Touat Mehdi, van den Bent Martin J, Wesseling Pieter, Figarella-Branger Dominique

Abstract excerpt

A working group of cIMPACT-NOW evaluated the literature on IDH-mutant gliomas for opportunities to improve pathology-based risk stratification and grading, especially at the interface of CNS WHO grades 2 and 3, since therapeutic decisions depend on risk assessment for clinical management. The group also evaluated newly described IDH-mutant glioma subgroups and considered multidisciplinary aspects of therapeutic...

Read the complete abstract on PubMed

Topics

Humans
Brain Neoplasms
DNA Methylation
Glioma
Isocitrate Dehydrogenase
Mutation

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Neoplasm Grading

Risk Assessment

Source

Open in PubMed Open full text

Identifiers

PMID: 42152226
DOI: 10.1093/neuonc/noag108
PMCID: PMC13550680

Genes

CDKN2A
CCND2
CDK4
CDK6
EGFR
MYCN
PDGFRA
RB1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 24 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

cIMPACT-NOW Update 12: Refining pathology-based risk stratification and grading for IDH-mutant gliomas.PMID 42152226Read ↗

cIMPACT ‐ NOW update 11: Proposal on adaptation of diagnostic criteria for IDH ‐ and H3 ‐wildtype diffuse high‐grade gliomas and for posterior fossa ependymal tumorsSemantic proximity Read ↗

Novel, improved grading system(s) for IDH-mutant astrocytic gliomas.Semantic proximity Read ↗

cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas.Semantic proximity Read ↗

Updates on the WHO diagnosis of IDH-mutant glioma.Semantic proximity Read ↗

Beyond the World Health Organization classification of central nervous system tumors 2016: what are the new developments for gliomas from a clinician's perspective?Semantic proximity Read ↗

IDH-mutant diffuse gliomas: tips and tricks in the era of genomic tumor classification.Semantic proximity Read ↗

IDH-mutant gliomas with additional class-defining molecular events.Semantic proximity Read ↗

Incorporating Advances in Molecular Pathology Into Brain Tumor DiagnosticsSemantic proximity Read ↗

Diffuse gliomas to date and beyond 2016 WHO Classification of Tumours of the Central Nervous System.Semantic proximity Read ↗

[World Health Organization Classification of Central Nervous System Tumours, 5th Edition:Points of the Update and the Current Status].Semantic proximity Read ↗

Molecular Characterization of IDH Wild-type Diffuse Astrocytomas: The Potential of cIMPACT-NOW Guidelines.Semantic proximity Read ↗

Clinical features, MRI, molecular alternations, and prognosis of astrocytoma based on WHO 2021 classification of central nervous system tumors: A single-center retrospective study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.